{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-019085","form_type":"8-K","ticker":"BPTH","cik":"0001133818","company_name":"BIO-PATH HOLDINGS, INC.","filed_at":"2023-11-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.320520+00:00","generated_at":"2026-06-08T01:58:38.103978+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Bio-Path Q3 net loss $3.2M; positive prexigebersen AML Phase 2 data","bullets":["Net loss of $3.2M ($0.32/sh) vs $3.5M ($0.49/sh) in Q3 2022, improvement from lower expenses and warrant income.","Cash $2.4M as of Sep 30, 2023, down from $10.4M at Dec 31, 2022; net cash used in ops $9.7M in nine months.","Positive Phase 2 interim data for prexigebersen in AML; results exceed outcomes of decitabine/venetoclax alone.","R&D expense $2.3M (down from $2.4M), G&A $1.0M (down from $1.2M) year-over-year.","KOL event in October with MD Anderson and Georgia Cancer Center experts discussing prexigebersen potential."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-019085","json":"https://secwatch.observer/filing/0001558370-23-019085.json","markdown":"https://secwatch.observer/filing/0001558370-23-019085.md","text":"https://secwatch.observer/filing/0001558370-23-019085.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1133818/000155837023019085/0001558370-23-019085-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1133818/000155837023019085/bpth-20231115x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T01:58:38.103978+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ca5dd486d06c77896678c15e889832679869bc42","claim":"BIO-PATH HOLDINGS, INC. reported third quarter ended September 30, 2023 results: net income net loss of $3.2 million, or $0.32 per share, EPS $0.32 per share.","evidence_excerpt":"The Company reported a net loss of $3.2 million, or $0.32 per share, for the three months ended September 30, 2023, compared to a net loss of $3.5 million, or $0.49 per share, for the three months ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1133818/000155837023019085/0001558370-23-019085-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Net income","value":"net loss of $3.2 million, or $0.32 per share"},{"label":"EPS","value":"$0.32 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}